Table 1.
Summary of the success rates of GCPDX under different conditions.
| Mice Strain | Implantation site | Tumor tissues | Engraftmentrate | Availablemodel | References |
|---|---|---|---|---|---|
| NSG | subcutaneous | 1mm3/fragment | 80% | – | (78) |
| NOD-SCID (F1) BALB/c-nude (Fn) |
subcutaneous | 3*3*3mm3/fragment | – | 5 | (79) |
| NOD/SCID | subcutaneous | 2*2*2mm3/fragment (F1) 3*3*3mm3/fragment (Fn) |
34.1% | 63/185 | (31) |
| BALB/c-nude | subcutaneous | 3*105/mL/cell | 28.1% | 9/32 | (80) |
| NMRI nude | – | 1-2 mm3/fragment | 27% | 27/100 | (81) |
| Nude | subcutaneous | 2mm3/fragment | 16.9% | 14/83 | (30) |
| SCID | 26.9% | 32/119 | |||
| Nude | subcutaneous/renal capsule | 3*3*3mm3/fragment | 8.0% | 6/75 | (82) |
| NOG | 10.5% | 9/86 | |||
| NOG | subcutaneous | 1mm3/fragment | 31.0% | 55/177 | (17) |
| NSG | 30.0% | 3/10 | |||
| SCID | 22.2% | 10/45 |